Schellens, J.H.

cancer breast cancer patient study breast treatment health topotecan analysis sample therapy recurrence outcome course haptoglobin difference tamoxifen administration effect methimazole country evaluation analyses schedule irinotecan result phenotype b.i.d survival netherland cost-effectiveness state number adjuvant women table carryover effect trial characteristic health states disease method level ratio breast cancer patients utility diarrhea pharmacokinetic model protein value sensitivity concentration event horizon hazard haptoglobin phenotype carryover productivity exemestane citation purposes postmenopausal women page number adjuvant therapy -38 time horizon oncol 5 years impact grade letrozole toxicity pharmacoeconomic modeling research participant perspective 21 days article sn -38